AdipoGen Life Sciences


CHF 170.00
In stock
AG-MR-C0020-M01010 mgCHF 170.00
AG-MR-C0020-M05050 mgCHF 680.00
More Information
Product Details
Synonyms 7-Bromoindirubin-3'-oxime
Product Type Chemical


MW 356.2
CAS 916440-85-2
Purity Chemicals ≥99% (NMR)
Appearance Dark red solid.
Solubility Soluble in DMSO or ethanol.
Reconstitution Stock solutions can be made up to 10mM in DMSO.
Identity Determined by 1H-NMR.
Smiles O\N=C1\C(\NC2=CC=CC=C\12)=C1\C(=O)NC2=C1C=CC=C2Br
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Anticancer compound.
  • Caspase-independent, non-apoptotic cell death inducer.
  • ATP-competitive Flt3 inhibitor.
  • Necrosis inducer.
  • Aurora B and C kinase inhibitor.
  • DYRK1A and DYRK 2 (Dual-specificity tyrosine phosphorylation-regulated kinase) inhibitor.
  • Inflammasome activator.
Product References
  1. Indirubin, the red shade of indigo: L. Meijer, et al. (Editors): In «Life in Progress», Station Biologique, Roscoff, 297 pp. (2006)
  2. 3'-substituted 7-Halogenoindirubins, a new class of cell death inducing agents: Y. Ferandin, et al.; J. Med. Chem. 49, 4638 (2006)
  3. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2008)
  4. Inverse in silico screening for identification of kinase inhibitor targets: S. Zahler, et al.; Chem. Biol. 14, 1207 (2007)
  5. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007)
  6. 7-Bromoindirubin-3'-oxime uncovers a serine protease-mediated paradigm of necrotic cell death: J. Ribas, et al.; Biochem. Pharmacol. 76, 39 (2008)
  7. Cutting edge: Necrosis activates the NLRP3 inflammasome: H. Li, et al.; J. Immunol. 183, 1528 (2009)
  8. Anticancer effects and antimetastatic mechanisms of novel indirubin derivatives: C.A. Kressirer; Diss. Ludwig-Maximilians-Universitaet Munchen, (2010)
  9. Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells: K.A. Nicolaou, et al.; BBRC 425, 76 (2012)
  10. From Tyrian purple to kinase modulators: naturally halogenated indirubins and synthetic analogues: K. Vougogiannopoulou & AL. Skaltsounis; Planta Med. 78, 1518 (2012)
  11. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling: L. Liu, et al.; Cancer Biol. Ther. 13, 1255 (2012)
  12. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases: V. Myrianthopoulos, et al.; ACS Med. Chem. Lett. 4, 22 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.